TOT BIOPHARM International Valuation
Is 1875 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 1875 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 1875's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 1875's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1875?
Key metric: As 1875 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 1875's PE Ratio? | |
|---|---|
| PE Ratio | 139.6x |
| Earnings | CN¥8.97m |
| Market Cap | CN¥1.25b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.3x |
| Enterprise Value/EBITDA | 16.6x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 1875's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 7.4x | ||
2142 HBM Holdings | 5.2x | n/a | HK$865.1m |
1061 Essex Bio-Technology | 5.7x | n/a | HK$1.5b |
690 Uni-Bio Science Group | 3.9x | n/a | HK$388.1m |
2696 Shanghai Henlius Biotech | 14.8x | 11.5% | HK$11.0b |
1875 TOT BIOPHARM International | 139.6x | n/a | HK$1.3b |
Price-To-Earnings vs Peers: 1875 is expensive based on its Price-To-Earnings Ratio (139.6x) compared to the peer average (7.4x).
Price to Earnings Ratio vs Industry
How does 1875's PE Ratio compare vs other companies in the Asian Biotechs Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 1875 is expensive based on its Price-To-Earnings Ratio (139.6x) compared to the Asian Biotechs industry average (31.2x).
Price to Earnings Ratio vs Fair Ratio
What is 1875's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 139.6x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 1875's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
3SBio
HK$13.7b
An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.
1530
HK$5.83
7D
-3.3%
1Y
-17.5%
China Shineway Pharmaceutical Group
HK$6.3b
An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.
2877
HK$8.33
7D
-9.8%
1Y
n/a
United Laboratories International Holdings
HK$18.4b
An investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products.
3933
HK$10.12
7D
-5.9%
1Y
34.2%